These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Neurologic complications of chemotherapy. Macdonald DR Neurol Clin; 1991 Nov; 9(4):955-67. PubMed ID: 1758434 [TBL] [Abstract][Full Text] [Related]
3. Central nervous system toxicities of chemotherapeutic agents. Peddi PF; Peddi S; Santos ES; Morgensztern D Expert Rev Anticancer Ther; 2014 Jul; 14(7):857-63. PubMed ID: 24745349 [TBL] [Abstract][Full Text] [Related]
4. [Cytostatic therapy: neurologic and psychiatric syndromes]. Strian F; Maurach R Med Klin; 1980 Jun; 75(13):478-84. PubMed ID: 6997713 [No Abstract] [Full Text] [Related]
5. Neurological complications of chemotherapy to the central nervous system. Newton HB Handb Clin Neurol; 2012; 105():903-16. PubMed ID: 22230541 [TBL] [Abstract][Full Text] [Related]
6. [Neurotoxic side effects of cytostatic therapy (author's transl)]. Strian F; Maurach R Fortschr Neurol Psychiatr; 1981 Apr; 49(4):152-63. PubMed ID: 7239402 [TBL] [Abstract][Full Text] [Related]
7. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Verstappen CC; Heimans JJ; Hoekman K; Postma TJ Drugs; 2003; 63(15):1549-63. PubMed ID: 12887262 [TBL] [Abstract][Full Text] [Related]
8. [Side effects of cytotoxic drugs on the nervous system]. Mintz U; Kuritzky A Harefuah; 1976 Nov; 91(9):294-7. PubMed ID: 795752 [No Abstract] [Full Text] [Related]
12. Hypersensitivity reactions to cancer chemotherapeutic agents. Weiss RB; Bruno S Ann Intern Med; 1981 Jan; 94(1):66-72. PubMed ID: 7004302 [TBL] [Abstract][Full Text] [Related]
13. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Sioka C; Kyritsis AP Cancer Chemother Pharmacol; 2009 Apr; 63(5):761-7. PubMed ID: 19034447 [TBL] [Abstract][Full Text] [Related]
14. [Neurological disorders induced by antineoplastic drugs]. Kuzuhara S No To Shinkei; 1992 Dec; 44(12):1059-66. PubMed ID: 1296725 [No Abstract] [Full Text] [Related]
15. [Neurological problems in malignant hemopathies in children. II. Neurotoxicity of antiblastic drugs and radiotherapy]. Galletti F; Sturniolo MG Minerva Pediatr; 1982 Jun; 34(11):485-91. PubMed ID: 6752689 [No Abstract] [Full Text] [Related]
16. Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities. Kwong YL; Yeung DY; Chan JC Ann Hematol; 2009 Mar; 88(3):193-201. PubMed ID: 19050889 [TBL] [Abstract][Full Text] [Related]
17. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284 [TBL] [Abstract][Full Text] [Related]
18. Renal complications of cytotoxic therapy. Healy HG; Clarkson AR Aust N Z J Med; 1983 Oct; 13(5):531-9. PubMed ID: 6228218 [TBL] [Abstract][Full Text] [Related]
19. Biochemical modulation: application of laboratory models to the clinic. Leyland-Jones B; O'Dwyer PJ Cancer Treat Rep; 1986 Jan; 70(1):219-29. PubMed ID: 3510736 [No Abstract] [Full Text] [Related]
20. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]